Gene therapy shows promise in the management of inherited peripheral neuropathy and the complex array of symptoms that patients experience. Gene therapy holds promise in the management of peripheral neuropathies and in significant improvement of quality of life for patients.
Investigators sought to compare the long-term clinical and cost effectiveness of levetiracetam vs valproate in patients with newly diagnosed generalized or unclassifiable epilepsy.
Currently, the FDA-approved route of administration of Tysabri for MS is through intravenous infusion.
Life expectancy among people with HIV receiving antiretroviral therapy (ART) has significantly improved in Latin America and the Caribbean.
Data analysis revealed that CGRP mAbs were discontinued more frequently than onabotulinumtoxinA (23% vs 3%).
Hizentra is indicated for the treatment of adult patients with CIDP as maintenance therapy to prevent relapse of neuromuscular disability and impairment.
Using systematic video analysis, researchers assessed the efficacy of nelotanserin for symptomatic treatment of REM sleep behavior disorder in patients with dementia.
AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
Percutaneous peripheral nerve stimulation reduces acute pain and opioid requirements in the week following orthopedic surgery.
A pill to treat COVID-19 is being developed by Pfizer and could be available by the end of the year.
